Chenodeoxycholic acid-(2,2,4,4-d4) A83259 (Previously 330259) 5ß-cholanic acid-3α,7α-diol (2,2,4,4-d4)
Chenodeoxycholic Acid-(2,2,4,4-d4) is a stable isotope of one of the main bile acids (BAs) in the human body, chenodeoxycholic acid (chenodiol).
Chenodeoxycholic acid is a primary carboxy bile acid, derived in liver hepatocytes from cholesterol catabolism through several enzyme-catalyzed steps. Chenodiol salts are called chenodeoxycholates. Chenodeoxycholic acid is epimeric with ursodiol. The metabolite often occurs as one of its conjugated derivatives—N-glycochenodeoxycholic acid and N-taurochenodeoxycholic acid.
Chenodeoxycholic acid, together with other BAs, forms mixed micelles that contain lecithin. They solubilize cholesterol and thus aid its excretion, as well as facilitate lipid digestion.
The primary bile acid also shows anticholelithogenic effects and finds application in medical treatment to dissolve gallstones. Chenodiol is used in therapy of cerebrotendinous xanthomatosis as well. In addition, administration of chenodeoxycholic acid is related to frequent diarrhea episodes, so the compound is considered as a treatment of constipation and for enhancing colonic transit, alongside improving bowel function.
Recently, chenodeoxycholic acid has been the subject of studies for its potential ability to participate in the therapy of Hepatitis C infection.
However, the compound is also linked to some pathological conditions. Chenodiol is thought to be involved in liver damage via hepatotoxicity.
Chenodeoxycholic acid is the most powerful BA in stimulating the nuclear BA receptor: farnesoid X receptor. This receptor is part of the nuclear receptor superfamily and plays a key role in the regulation of numerous metabolic pathways.
Avanti Research produces quality Chenodeoxycholic Acid-(2,2,4,4-d4), available for your research analysis today.
